Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Barrett Mueller K
,
Lu Q
,
Mohammad NN
,
Luu V
,
McCurley A
,
Williams GH
,
Adler GK
,
Karas RH
,
Jaffe IZ
.
???displayArticle.abstract???
The steroid hormone aldosterone (aldo) contributes to cardiovascular disease in animal models and in humans. Aldo activates the mineralocorticoid receptor (MR), a hormone-activated transcription factor, and indeed, pharmacological MR inhibition improves cardiovascular outcomes. Because the incidence of cardiovascular disease is lower in premenopausal women, we hypothesized that estrogen (E2) signaling through the estrogen receptor (ER) may protect the vasculature by inhibiting the detrimental effects of aldo signaling through the MR. We demonstrate that E2-activated ER inhibits MR-mediated gene transcription from the mouse mammary tumor virus reporter in human embryonic kidney-293 cells. In contrast, aldo-activated MR does not affect ER-mediated gene transcription. The ERα N terminus (amino acids 1-253) containing part of the DNA-binding domain is sufficient to inhibit MR genomic function, although point mutations reveal that DNA binding, ligand-independent activation, and rapid nongenomic ERα signaling are not required for this effect. Furthermore, ERα and MR are part of a complex in cell lysates, with amino acids 1-233 of the ERα N terminus being sufficient to complex with the MR. Overall, the ability of ERα to inhibit MR-mediated gene transcription correlates with the ability of ERα segments to both localize to the nucleus and complex with the MR. In cultured vascular endothelial cells expressing ERα, E2 inhibits aldo induction of the vascular MR target gene intercellular adhesion molecule-1 (ICAM-1). ICAM-1 induction by endothelial MR is known to promote vascular inflammation that could contribute to the mechanism of aldo-induced atherosclerosis. E2 also inhibits aldo induction of ICAM-1 protein and prevents aldo-enhanced leukocyte adhesion to endothelial cells. These studies support a new model in which E2-activated ER in endothelial cells forms a complex with MR in the nucleus to modulate MR regulation of the proinflammatory gene ICAM-1. Estrogen inhibition of MR regulation of genes that contribute to cardiovascular disease may be a new mechanism by which premenopausal women are protected from cardiovascular disease.
Arias-Loza,
Both estrogen receptor subtypes, alpha and beta, attenuate cardiovascular remodeling in aldosterone salt-treated rats.
2007, Pubmed
Arias-Loza,
Both estrogen receptor subtypes, alpha and beta, attenuate cardiovascular remodeling in aldosterone salt-treated rats.
2007,
Pubmed
Arriza,
Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor.
1987,
Pubmed
Azibani,
Aldosterone mediates cardiac fibrosis in the setting of hypertension.
2013,
Pubmed
Bairey Merz,
Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study.
2003,
Pubmed
Barrett,
Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation.
2013,
Pubmed
Bechlioulis,
Endothelial function, but not carotid intima-media thickness, is affected early in menopause and is associated with severity of hot flushes.
2010,
Pubmed
Bernelot Moens,
Rapid estrogen receptor signaling is essential for the protective effects of estrogen against vascular injury.
2012,
Pubmed
Caprio,
Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion.
2008,
Pubmed
Caprio,
Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis.
2007,
Pubmed
Clapauch,
Early postmenopausal women with cardiovascular risk factors improve microvascular dysfunction after acute estradiol administration.
2012,
Pubmed
Clyne,
Purification and characterization of recombinant human mineralocorticoid receptor.
2009,
Pubmed
Danser,
Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans.
1998,
Pubmed
Deanfield,
Endothelial function and dysfunction: testing and clinical relevance.
2007,
Pubmed
Dooley,
Non-genomic actions of aldosterone: from receptors and signals to membrane targets.
2012,
Pubmed
Fuller,
Mechanisms of ligand specificity of the mineralocorticoid receptor.
2012,
Pubmed
Fuller,
Duelling receptors: estrogen receptor versus mineralocorticoid receptor in the cardiovascular system.
2014,
Pubmed
Giannotti,
Endothelial dysfunction as an early sign of atherosclerosis.
2007,
Pubmed
Go,
Heart disease and stroke statistics--2013 update: a report from the American Heart Association.
2013,
Pubmed
Gomez-Sanchez,
Development of a panel of monoclonal antibodies against the mineralocorticoid receptor.
2006,
Pubmed
Greschik,
Structure-activity relationship of nuclear receptor-ligand interactions.
2003,
Pubmed
Hannemann,
Plasma aldosterone levels and aldosterone-to-renin ratios are associated with endothelial dysfunction in young to middle-aged subjects.
2011,
Pubmed
Hodgin,
Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in Apoe-/- mice.
2001,
Pubmed
Hodgin,
Minireview: estrogen and mouse models of atherosclerosis.
2002,
Pubmed
Ivanes,
Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure.
2012,
Pubmed
Jaffe,
Placental growth factor mediates aldosterone-dependent vascular injury in mice.
2010,
Pubmed
Jaffe,
Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells.
2005,
Pubmed
Kalantaridou,
Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy.
2004,
Pubmed
Kannel,
Menopause and risk of cardiovascular disease: the Framingham study.
1976,
Pubmed
Karas,
Effects of estrogen on the vascular injury response in estrogen receptor alpha, beta (double) knockout mice.
2001,
Pubmed
Karas,
Growth factor activation of the estrogen receptor in vascular cells occurs via a mitogen-activated protein kinase-independent pathway.
1998,
Pubmed
Kerber,
Euestrogenemia and the mineralocorticoid receptor.
2015,
Pubmed
Levin,
Extranuclear estrogen receptor's roles in physiology: lessons from mouse models.
2014,
Pubmed
Lombès,
Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor.
1992,
Pubmed
Lombès,
Characterization of the interaction of the human mineralocorticosteroid receptor with hormone response elements.
1993,
Pubmed
Lother,
Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function.
2011,
Pubmed
Lu,
Regulation of estrogen receptor alpha-mediated transcription by a direct interaction with protein phosphatase 2A.
2003,
Pubmed
Lu,
Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha.
2004,
Pubmed
Luther,
Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
2012,
Pubmed
Mangelsdorf,
The RXR heterodimers and orphan receptors.
1995,
Pubmed
McGraw,
Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism.
2013,
Pubmed
McGraw,
Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications.
2013,
Pubmed
Mettu,
The nuclear receptor-coactivator interaction surface as a target for peptide antagonists of the peroxisome proliferator-activated receptors.
2007,
Pubmed
Miller,
Impact of gender on the renal response to angiotensin II.
1999,
Pubmed
Milliez,
Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.
2005,
Pubmed
Nagase,
Mineralocorticoid receptor activation in obesity hypertension.
2009,
Pubmed
Nagase,
Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: role of small GTPase Rac1.
2012,
Pubmed
Newfell,
Aldosterone regulates vascular gene transcription via oxidative stress-dependent and -independent pathways.
2011,
Pubmed
Ossewaarde,
Age at menopause, cause-specific mortality and total life expectancy.
2005,
Pubmed
Pedram,
ERβ selective agonist inhibits angiotensin-induced cardiovascular pathology in female mice.
2013,
Pubmed
Pippal,
Structural and functional characterization of the interdomain interaction in the mineralocorticoid receptor.
2009,
Pubmed
Pitt,
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
2003,
Pubmed
Pitt,
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
2003,
Pubmed
Pitt,
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
1999,
Pubmed
Pojoga,
Activation of the mineralocorticoid receptor increases striatin levels.
2012,
Pubmed
Pruthi,
Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors.
2014,
Pubmed
Rocha,
Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart.
2002,
Pubmed
Saltiki,
Endogenous estrogen levels are associated with endothelial function in males independently of lipid levels.
2010,
Pubmed
Schunkert,
Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women.
1997,
Pubmed
Shibata,
Mineralocorticoid receptor phosphorylation regulates ligand binding and renal response to volume depletion and hyperkalemia.
2013,
Pubmed
Sullivan,
Estrogen inhibits the response-to-injury in a mouse carotid artery model.
1995,
Pubmed
Ueda,
Rapid estrogen receptor signaling mediates estrogen-induced inhibition of vascular smooth muscle cell proliferation.
2013,
Pubmed
Ueda,
Genome-wide analysis of murine renal distal convoluted tubular cells for the target genes of mineralocorticoid receptor.
2014,
Pubmed
Usher,
Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice.
2010,
Pubmed
Vasan,
Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study.
2004,
Pubmed
Wang,
Estrogen receptor beta mediates increased activation of PI3K/Akt signaling and improved myocardial function in female hearts following acute ischemia.
2009,
Pubmed
Weber,
Aldosterone in congestive heart failure.
2001,
Pubmed
Zannad,
Eplerenone in patients with systolic heart failure and mild symptoms.
2011,
Pubmed